Forte BiosciencesFBRX
About: Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).
Employees: 14
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 4
12% more funds holding
Funds holding: 26 [Q4 2024] → 29 (+3) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
60% less capital invested
Capital invested by funds: $97.1M [Q4 2024] → $39.3M (-$57.8M) [Q1 2025]
214.08% less ownership
Funds ownership: 292.87% [Q4 2024] → 78.79% (-214.08%) [Q1 2025]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
Chardan Capital Daniil Gataulin 17% 1-year accuracy 10 / 58 met price target | 677%upside $61 | Buy Maintained | 1 Apr 2025 |
Financial journalist opinion









